CULTURE BRANDS UNIVERSITIES UNITED NATIONS
HOME SUBSCRIBE ABOUT US CONTACT US



World Press Freedom Day


OSCARS


Google News


UNESCO CREATIVE CITIES NETWORK





« OMEGA Counts Down to the Olympic Games with The Seamaster Diver 300M Tokyo 2020. | Main | Princeton Review releases its Best Value Colleges List & Rankings for 2021. »

April 19, 2021

Oxford University launches Human Challenge Trial to study immune response to COVID-19.


Oxford University


Oxford, April 19, 2021 — Though the COVID-19 pandemic has been active for a year, it is unknown what happens when people who have already had COVID-19 get infected for a second time.

Researchers at the University of Oxford have launched a human challenge trial to look at what kind of immune response can stop people from becoming re-infected. They also want to see how the immune system reacts the second time around. A human challenge trial in medical research is a carefully controlled study that involves purposefully infecting a subject with a pathogen or bug to study the effects of that infection.

The study will take place in two phases with different participants in each stage. The first phase, which will start in April 2021, will establish the lowest dose of virus in approximately 50% of previously naturally infected people and can take hold and start replicating but produce little or no symptoms. In the second phase of the study, expected to begin in summer 2021, all participants will be infected with the standardized dose of the virus, which was established in phase one.

For phase one, up to 64 healthy participants between the ages of 18 - 30 who previously got naturally infected with COVID-19 will be re-exposed to the virus in carefully controlled conditions. The virus used in the study will be the original strain from Wuhan, China. The participants will be quarantined in a specially designed hospital suite for a minimum of 17 days under the care of the research team. They will undergo numerous medical tests, including CT scans of the lungs and MRI scans of the heart. The team would minimize the risks to participants by ensuring that those who take part are completely fit and well and have completely recovered from their first infection with COVID.

Any participants who develop any symptoms will receive medical treatment with the Regeneron monoclonal antibody. They will only be discharged from the quarantine unit when they are no longer infected and not at risk of infecting others. The entire length of the study will be 12 months, including a minimum of eight follow-up appointments after discharge. Participation in the survey is entirely voluntary.

Helen McShane, Professor of Vaccinology at the Department of Paediatrics, University of Oxford and Chief Investigator on the study, said, ‘Challenge studies tell us things that other tasks cannot because, unlike natural infection, they are tightly controlled. When we re-infect these participants, we will know precisely how their immune system has reacted to the first COVID infection, exactly when the second infection occurs, and exactly how much virus they got. As well as enhancing our basic understanding, this may help us design tests that can accurately predict whether people are protected.

‘In phase two, we will explore two different things. First, we will define the baseline immune response in the volunteers very carefully before we infect them. We will then infect them with the dose of virus chosen from the first study and measure how much virus we can detect after infection. We will then be able to understand what kind of immune responses protect against re-infection. Second, we will measure the immune response at several time points after infection to understand the virus’s immune response.

‘A challenge study allows us to make these measurements very precisely because we know exactly when someone is infected. The information from this work will allow us to design better vaccines and treatments and understand if people are protected after having COVID and for how long.’

Wellcome Trust is funding the study. Shobana Balasingam, Vaccines Senior Research Advisor at Wellcome, said, ‘There are still many unknowns surrounding this virus and human infections studies can enable us to learn a lot about Covid-19. This study has the potential to transform our understanding by providing high-quality data on how our immune system responds to a second infection with this virus.

‘The findings could have important implications for how we handle Covid-19 in the future and inform not just vaccine development but also research into the range of effective treatments that are also urgently needed. Keeping up the pace of scientific research and development, through crucial studies such as this, remain the only way we will truly get ahead of this pandemic and bring it under control.’

Source: University of Oxford

|GlobalGiants.Com|




del.icio.us StumbleUpon reddit Facebook Google Plus Tweet This Seed This on Newsvine

Edited & Posted by the Editor | 2:36 PM | Link to this Post






Start from HOME Go to Top


TRANS WORLD EXPORTS